PTGX — Protagonist Therapeutics, Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1377121 ·
Last close
$99.98
Market Cap
$6.43B
52W High
$107.84
52W Low
$87.15
ADV30
582,541
Next earnings
2026-05-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 56,368,000 | — | -3,648,000 | 3,783,000 | 697,459,000 | 193,712,000 | 41,986,000 |
| Dec 2025 | 7,437,000 | — | -50,355,000 | -44,384,000 | 668,188,000 | 128,390,000 | 53,481,000 |
| Sep 2025 | 4,712,000 | — | -46,421,000 | -39,339,000 | 701,688,000 | 113,713,000 | 56,251,000 |
| Jun 2025 | 5,546,000 | — | -42,041,000 | -34,771,000 | 718,006,000 | 168,543,000 | 49,988,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-116,635,000
Investing CF
$135,962,000
Financing CF
$34,795,000
CapEx
$-1,260,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.81
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-466,888,000
Inventory
—
Receivables
$57,122,000
ST Investments
$354,074,000
EBIT TTM
$-142,465,000
Pretax Income TTM
$-115,375,000
Interest Exp TTM
—
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$74,063,000
EBITDA
$-141,016,992
Free Cash Flow
$-77,664,624
Enterprise Value
$5,841,035,264
Total Cash
$547,785,984
Total Debt
$9,776,000
Shares Out
64,311,373
Trailing EPS
$-1.82
Book Value
$10.21
ROE
-17.1%
ROA
-12.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 46,016,000 | -158,127,000 | -130,149,000 | 668,188,000 | 53,481,000 | — | 57,671,000 |
| Dec 2024 | 434,433,000 | 252,843,000 | 275,188,000 | 744,725,000 | 69,430,000 | — | 184,152,000 |
| Dec 2023 | 60,000,000 | -93,652,000 | -78,955,000 | 357,951,000 | 21,274,000 | — | -70,236,000 |
| Dec 2022 | 26,581,000 | -131,373,000 | -127,393,000 | 247,928,000 | 32,320,000 | — | -108,137,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-7,084,000
OpCashFlow TTM
$0
Assets (Latest)
$93,990,000
Forward EPS
$-0.68
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SYRE | Spyre Therapeutics, Inc. | $6.40B | $73.65 | — |
| CORT | CORCEPT THERAPEUTICS INC | $6.48B | $60.36 | — |
| ALKS | Alkermes plc. | $6.23B | $37.35 | — |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $6.16B | $89.82 | — |
| CNTA | Centessa Pharmaceuticals plc | $6.16B | $39.78 | — |
News headlines (Yahoo Finance, 1h cache)
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
2026-05-18 18:43 · Yahoo
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?
2026-05-18 18:25 · Yahoo
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?
2026-05-18 18:10 · Yahoo
Analyst Forecasts For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Are Surging Higher
2026-05-11 13:05 · Yahoo
Protagonist Therapeutics, Inc. Surprised Analysts With A Profit, And Analysts Boosted Their EPS Forecasts
2026-05-08 12:25 · Yahoo
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 141% One Year Surge?
2026-05-07 01:14 · Yahoo
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-05 20:05 · Yahoo
Protagonist Therapeutics Inc. (PTGX): Billionaire Tom Steyer Likes Upside Potential of This Stock
2026-05-02 14:49 · Yahoo
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
2026-04-28 13:05 · Yahoo
Protagonist Therapeutics Inc. (PTGX): Billionaire Joe Edelman Likes This Stock
2026-04-27 14:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.